CARE
Carter Bankshares, Inc.
Next earnings Jul 22, 2026 · consensus $0.79 EPS, $57.0M rev
$33.60
▲ +2.82%$33.60▲ +99.22%
over 1Y
L $16.87EODHDH $33.60
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.8%
1W+6.6%
1M+25.2%
3M+47.4%
YTD+73.6%
1Y+99.2%
Sell
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 10 analysts
Buy
Improving earnings can't justify a 23.7x P/E and ~1.7x P/B on a 7.5% ROE community bank with heavy CRE exposure.
Diluted EPS $1.38 · FY2025
The read
It screens cheap (~28% below fair value), but the weak fundamentals are why — more potential value trap than bargain.
Carter Bankshares is a $4.85B-asset community bank concentrated in NC/VA/SC whose 2025 results (EPS $1.38, +30%; net income $31.4M, +28%) reflect a real recovery — but the stock has gotten ahead of the franchise. Return on equity is only 7.5%, well below a typical bank cost of equity, yet the shares trade at ~1.73x book ($726M cap on $420M equity) and 23.7x earnings — multiples normally reserved for high-ROE specialty banks, not a 7.5%-ROE regional. The most telling tell: the company's own $20M buyback was executed at a $17.78 weighted-average price, and the newly authorized program (Feb 2026, $10M) is now sized small, suggesting management sees less value at $32.74.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $17.5M | $18.3M | $17.3M | $19.4M | $20.3M |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $31.6M | $50.1M | $23.4M | $24.5M | $31.4M |
| Diluted EPS | $1.19 | $2.03 | $1.00 | $1.06 | $1.38 |
| Net margin | 180.7% | 273.4% | 135.4% | 126.3% | 154.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF23.4
PEG (trailing)0.87
Earnings yield4.2%
FCF yield4.3%
Quality & risk
ROIC (est.)—
Free cash flow$31.8M
Total debt—
Net cash$105M
Piotroski F-Score6/6
Capital returns
Buyback yield2.7%
Dividend yield (est.)0.0%
Shareholder yield2.7%
Shares Δ YoY-4.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Officer / director change2026-06-24
Executive officer change disclosed; exhibits filed under Item 5.02/9.01
- 8-K Reg FD disclosure2026-05-29
Annual meeting voting results disclosed (Item 5.07)
- 8-K Shareholder vote2026-05-29
Annual meeting voting results disclosed (Item 5.07)
- 10-Q Quarterly report2026-05-07
Q1 2026 results; loan growth and CRE concentration trends continue
- 8-K Reg FD disclosure2026-05-01
Other event disclosure (Item 8.01)
- 8-K Other event2026-05-01
Other event disclosure (Item 8.01)
- 8-K Other event2026-04-23
Q1 earnings release likely under Item 8.01 with exhibits
- DEF 14A Proxy statement2026-04-15
2026 proxy: director slate, exec comp and auditor ratification
- 10-K Annual report2026-03-05
FY25 EPS $1.38 +30%; loans +7% to $3.9B; new $10M buyback authorized
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-182026-06-24open ↗8-KPeriod ending 2026-05-292026-05-29open ↗8-KPeriod ending 2026-05-272026-05-29open ↗4Period ending 2026-05-212026-05-26open ↗SCHEDULE 13G/AFiling2026-05-15open ↗4Period ending 2026-05-122026-05-12open ↗4Period ending 2026-05-082026-05-11open ↗10-QPeriod ending 2026-03-312026-05-07open ↗4Period ending 2026-05-062026-05-07open ↗4Period ending 2026-05-052026-05-06open ↗8-KPeriod ending 2026-05-012026-05-01open ↗8-KPeriod ending 2026-05-012026-05-01open ↗
Frequently asked
- Is Carter Bankshares, Inc. (CARE) a buy?
- CARE currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Improving earnings can't justify a 23.7x P/E and ~1.7x P/B on a 7.5% ROE community bank with heavy CRE exposure.
- What is CARE's fair value?
- A Modified-Graham model based on CARE's SEC fundamentals estimates a fair value of about $42.91. It is an estimate from reported earnings, not a price target.
- Is CARE overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, CARE currently appears undervalued relative to its SEC-grounded earnings power.
- What is Carter Bankshares, Inc.'s quality score?
- CARE scores 68.6470588235294/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001829576, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 3:15:50 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.